Immatics N.V. (IMTX)

10,77 -0,12 (-1,10%) Alla chiusura: 04:00PM EDT

Immatics N.V.

Paul-Ehrlich-Strasse 15
Tübingen 72076
Germany
49 7071 5397 0
https://www.immatics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 432

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Harpreet Singh Ph.D.	CEO, MD, Member of Management Board & Executive Director	889,48k	N/D	1975
Dr. Toni Weinschenk Ph.D.	Co-Founder & Chief Innovation Officer	N/D	N/D	1974
Mr. Arnd Christ MBA	Chief Financial Officer	N/D	N/D	1966
Mr. Steffen Walter Ph.D.	Chief Operations Officer	N/D	N/D	1977
Mr. Edward A. Sturchio J.D.	General Counsel & Secretary	N/D	N/D	1976
Dr. Carsten Reinhardt M.D., Ph.D.	Chief Development Officer	N/D	N/D	1967
Mr. Cedrik M. Britten M.D.	Chief Medical Officer	N/D	N/D	1976
Mr. Jordan Silverstein	Head of Strategy	N/D	N/D	1980
Dr. Hans-Georg Rammensee Ph.D.	Co-Founder & Member of the Scientific Advisory Board	N/D	N/D	N/D
Mr. Ephraim Hofsäß M.Sc.	Vice President of SEC Reporting & Accounting	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Governance aziendale

L'ISS Governance QualityScore di Immatics N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.